A Phase 1 Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of SKB571 for Injection in Subjects with Advanced Solid Tumors
Latest Information Update: 18 Dec 2024
Price :
$35 *
At a glance
- Drugs SKB 571 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Sichuan Kelun Pharmaceutical Research Institute
- 18 Dec 2024 New trial record